CATALYST PHARMACEUTICALS, INC.
355 Alhambra Circle
Suite 1250
Coral Gables, Florida 33134
July 30, 2020
VIA EDGAR (CORRESPONDENCE)
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
| Re: | Catalyst Pharmaceuticals, Inc. |
Registration Statement on Form S-3 |
Registration No. 333-240052 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Catalyst Pharmaceuticals, Inc. (“Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Washington, D.C. time, on July 31, 2020, or as soon thereafter as is practicable.
The Company hereby acknowledges and confirms its understanding that the Company and its management are responsible for the accuracy and adequacy of the disclosure in the Registration Statement, notwithstanding any review, comments, action or absence of action by the staff of the SEC.
Please call Philip Schwartz (at 954-468-2455) at Akerman LLP as soon as the Registration Statement has been declared effective.
Thank you for your courtesy and cooperation.
| Very Truly Yours, |
| /s/ Patrick J. McEnany |
| Patrick J. McEnany |
| Chairman, President and CEO |
| Cc: | Alan Campbell (SEC) |
Philip B. Schwartz, Esq. |
